Daily Stock Analysis, AXSM, Axsome Therapeutics Inc, priceseries

Axsome Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
23.37
Close
24.18
High
24.35
Low
21.85
Previous Close
23.70
Daily Price Gain
0.48
YTD High
38.42
YTD High Date
Jan 3, 2022
YTD Low
21.85
YTD Low Date
Jan 24, 2022
YTD Price Change
-13.65
YTD Gain
-36.08%
52 Week High
78.00
52 Week High Date
Feb 4, 2021
52 Week Low
19.38
52 Week Low Date
Aug 19, 2021
52 Week Price Change
-51.38
52 Week Gain
-68.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 16. 2017
4.10
Jul 3. 2017
5.15
11 Trading Days
25.66%
Link
LONG
Sep 15. 2017
4.95
Oct 10. 2017
5.74
17 Trading Days
15.91%
Link
LONG
Apr 26. 2018
3.00
May 21. 2018
3.33
17 Trading Days
11.00%
Link
LONG
Aug 28. 2018
3.00
Sep 10. 2018
3.15
8 Trading Days
5.10%
Link
LONG
Oct 15. 2018
3.35
Nov 5. 2018
3.90
15 Trading Days
16.38%
Link
LONG
Jan 30. 2019
8.33
Feb 7. 2019
8.78
6 Trading Days
5.43%
Link
LONG
Mar 6. 2019
8.86
Apr 1. 2019
12.84
18 Trading Days
44.90%
Link
LONG
Apr 22. 2019
15.12
May 23. 2019
21.39
23 Trading Days
41.48%
Link
LONG
Sep 11. 2019
25.18
Sep 23. 2019
27.16
8 Trading Days
7.87%
Link
LONG
Nov 13. 2019
25.70
Jan 3. 2020
93.83
34 Trading Days
265.08%
Link
LONG
Apr 22. 2020
69.88
May 8. 2020
88.79
12 Trading Days
27.06%
Link
LONG
Jun 17. 2021
66.54
Jun 29. 2021
70.05
8 Trading Days
5.27%
Link
LONG
Sep 15. 2021
27.72
Oct 4. 2021
32.73
13 Trading Days
18.08%
Link
LONG
Oct 11. 2021
32.62
Oct 25. 2021
39.47
10 Trading Days
21.00%
Link
LONG
Dec 16. 2021
33.51
Dec 29. 2021
35.23
8 Trading Days
5.13%
Link
Company Information
Stock Symbol
AXSM
Exchange
NasdaqGM
Company URL
http://www.axsome.com
Company Phone
212-203-5072
CEO
Herriott Tabuteau
Headquarters
New York
Business Address
25 BROADWAY, 9TH FLOOR, NEW YORK, NY 10004
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001579428
About

Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Description

Developing an oral formulation of an existing therapy for pain and osteoarthritis.